In patients with ischemic stroke and aphasia treated with cortexin plus mexidol, 24 of 34 (70.6%) had a speech questionnaire gain above 6 points and 10 (29.4%) had a gain of 6 or less.
In plain wordsIn patients with stroke and aphasia given cortexin plus mexidol, 70.6% had a large speech gain and 29.4% a small one.
- Outcome
- Not applicableSpeech recovery category (high ΔSQ >6 versus low ΔSQ ≤6)
- Study
n = 34
- Outcome group
- Cognition and memory · Nervous system and cognition
Measurements
- High recovery (ΔSQ >6)
- 24 patients
- cortexin plus mexidol
- High recovery (ΔSQ >6)
- 70.6%
- cortexin plus mexidol
- Low recovery (ΔSQ ≤6)
- 10 patients
- cortexin plus mexidol
- Low recovery (ΔSQ ≤6)
- 29.4%
- cortexin plus mexidol
Source sentences
The greatest efficacy was shown for cortexin in combination with mexidol: the ΔSQ >6 group included 24 (70.6%) and the group ΔSQ ≤6 10 (29.4%) patients out of 34 patients.
4 context sentences(design, population, supporting numbers)
The study included 257 patients (median age 60 (55; 72) years) with ischemic stroke and motor or sensorimotor aphasia.
The degree of speech recovery was characterized by an increase in the score on the scale of the speech questionnaire (SQ) on the 21st day from the beginning of the disease.
Patients were divided into low recovery (ΔSQ ≤6) and high recovery (ΔSQ >6) groups.
All patients received neuroprotectors of different groups.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).